{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:44:07Z","timestamp":1788399847591,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"FIS\/Fondos FEDER","award":["PI18\/01366"],"award-info":[{"award-number":["PI18\/01366"]}]},{"name":"FIS\/Fondos FEDER","award":["PI19\/00588"],"award-info":[{"award-number":["PI19\/00588"]}]},{"name":"FIS\/Fondos FEDER","award":["PI19\/00815"],"award-info":[{"award-number":["PI19\/00815"]}]},{"name":"FIS\/Fondos FEDER","award":["DTS18\/00032"],"award-info":[{"award-number":["DTS18\/00032"]}]},{"name":"ERA-PerMed-JTC2018","award":["KIDNEY ATTACK AC18\/00064"],"award-info":[{"award-number":["KIDNEY ATTACK AC18\/00064"]}]},{"name":"ERA-PerMed-JTC2018","award":["PERSTIGAN AC18\/00071"],"award-info":[{"award-number":["PERSTIGAN AC18\/00071"]}]},{"name":"ISCIII-RETIC REDinREN","award":["RD016\/0009"],"award-info":[{"award-number":["RD016\/0009"]}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["B2017\/BMD-3686"],"award-info":[{"award-number":["B2017\/BMD-3686"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40265-021-01656-1","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T11:03:49Z","timestamp":1640084629000},"page":"109-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-6328","authenticated-orcid":false,"given":"Jorge","family":"Rojas-Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"1656_CR1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"W Couser","year":"2017","unstructured":"Couser W. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12:983\u201397.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1656_CR2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/kisup.2012.20","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. Chapter 7: Idiopathic membranous nephropathy. KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int Suppl. 2012;2:186\u201397.","journal-title":"Kidney Int Suppl"},{"key":"1656_CR3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"KDIGO","year":"2021","unstructured":"KDIGO. 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1-276.","journal-title":"Kidney Int"},{"key":"1656_CR4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28:348\u201358.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36\u201346.","journal-title":"N Engl J Med"},{"key":"1656_CR6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","volume":"320","author":"C Ponticelli","year":"1989","unstructured":"Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989;320:8\u201313.","journal-title":"N Engl J Med"},{"key":"1656_CR7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9:444\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","volume":"48","author":"C Ponticelli","year":"1995","unstructured":"Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48:1600\u20134.","journal-title":"Kidney Int"},{"key":"1656_CR9","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18:1899\u2013904.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR10","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0002492021","author":"N Klomjit","year":"2021","unstructured":"Klomjit N, Zand L. Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy. Kidney360. 2021. https:\/\/doi.org\/10.34067\/KID.0002492021.","journal-title":"Kidney360."},{"key":"1656_CR11","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.13761119","volume":"15","author":"Y Peleg","year":"2020","unstructured":"Peleg Y, Bomback A, Radhakrishnan J. The evolving role of calcineurin inhibitors in treating lupus nephritis. Clin J Am Soc Nephrol. 2020;15:1066\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1656_CR12","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59:1484\u201390.","journal-title":"Kidney Int"},{"key":"1656_CR13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M, Barrio V, Ju\u00e1rez GF, Lu\u00f1o J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71:924\u201330.","journal-title":"Kidney Int"},{"key":"1656_CR14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000348475","volume":"181","author":"J Xu","year":"2013","unstructured":"Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang W, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol. 2013;181:152\u201362.","journal-title":"Contrib Nephrol"},{"key":"1656_CR15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/0886022X.2017.1325371","volume":"39","author":"Q Liang","year":"2017","unstructured":"Liang Q, Li H, Xie X, Qu F, Li X, Chen J. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Renal Fail. 2017;39:512\u20138.","journal-title":"Renal Fail"},{"key":"1656_CR16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","volume":"2","author":"R Ramachandran","year":"2017","unstructured":"Ramachandran R, Yadav AK, Kumar V, Pinnamaneni VST, Nada R, Ghosh R, et al. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017;2:610\u20136.","journal-title":"Kidney Int Rep."},{"key":"1656_CR17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","volume":"16","author":"TT Qiu","year":"2017","unstructured":"Qiu TT, Zhang C, Zhao HW, Zhou JW. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev. 2017;16:136\u201345.","journal-title":"Autoimmun Rev"},{"key":"1656_CR18","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41598-021-92678-y","volume":"11","author":"Q Wang","year":"2021","unstructured":"Wang Q, Li M, Cheng X, Xu G. Clinical efficacy, and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy. Sci Rep. 2021;11:1374. https:\/\/doi.org\/10.1038\/s41598-021-92678-y.","journal-title":"Sci Rep"},{"key":"1656_CR19","first-page":"28","volume":"100","author":"L Gong","year":"2021","unstructured":"Gong L, Xu M, Xu W, Tang W, Lu J, Jiang W, et al. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: a meta-analysis. Medicine. 2021;100:28.","journal-title":"Medicine"},{"key":"1656_CR20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","volume":"4","author":"A Segarra","year":"2009","unstructured":"Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009;4:1083\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1656_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","volume":"1","author":"M Waldman","year":"2016","unstructured":"Waldman M, Beck LH Jr, Braun M, Wilkins K, Balow JE, Austin HA III. Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab. Kidney Int Rep. 2016;1:73\u201384.","journal-title":"Kidney Int Rep."},{"key":"1656_CR22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11\u201321.","journal-title":"N Engl J Med"},{"key":"1656_CR23","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","volume":"9","author":"AP Bech","year":"2014","unstructured":"Bech AP, Hofstra JM, Brenchley PE, Wetzels JFM. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9:1386\u201392.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1656_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/nep.12737","volume":"22","author":"Y Takahashi","year":"2017","unstructured":"Takahashi Y, Ikezumi Y, Saitoh A. Rituximab protects podocyte and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B lymphocytes. Nephrology (Carlton). 2017;22:49\u201357.","journal-title":"Nephrology (Carlton)"},{"key":"1656_CR25","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46. https:\/\/doi.org\/10.1126\/scitranslmed.3002231.","journal-title":"Sci Transl Med."},{"key":"1656_CR26","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","volume":"14","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003;14:1851\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR27","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","volume":"5","author":"FC Fervenza","year":"2010","unstructured":"Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Soc Nephrol. 2010;5:2188\u201398.","journal-title":"Clin J Soc Nephrol."},{"key":"1656_CR28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","volume":"2","author":"P Cravedi","year":"2007","unstructured":"Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cell to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007;2:932\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1656_CR29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23:1416\u201325.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR30","first-page":"9","volume":"33","author":"P Zou","year":"2018","unstructured":"Zou P, Li H, Cai J, Chen Z, Li C, Li X. Therapy of rituximab in idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis. Chin Med Sci J. 2018;33:9\u201319.","journal-title":"Chin Med Sci J"},{"key":"1656_CR31","first-page":"8021","volume":"22","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bian L, Ma F-Z, Jia Y, Lin P. Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis. Eur Rev Med Pharm Sci. 2018;22:8021\u20139.","journal-title":"Eur Rev Med Pharm Sci."},{"key":"1656_CR32","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, van de Logt A-E, Justino J, Sevillano A, Caravaca-Font\u00e1n F, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99:986\u201398.","journal-title":"Kidney Int"},{"key":"1656_CR33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","volume":"8","author":"J Rojas-Rivera","year":"2015","unstructured":"Rojas-Rivera J, Fern\u00e1ndez-Ju\u00e1rez G, Ortiz A, Hofstra J, Gesualdo L, Tesar V, et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus steroids plus cyclophosphamide in patients with primary membranous nephropathy: the STARMEN study. Clin Kidney J. 2015;8:503\u201310.","journal-title":"Clin Kidney J"},{"key":"1656_CR34","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32:972\u201382.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR35","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","volume":"28","author":"JAJG van den Brand","year":"2017","unstructured":"van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28:2729\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ckj\/sfz127","volume":"12","author":"J Rojas-Rivera","year":"2019","unstructured":"Rojas-Rivera J, Carriazo S, Ortiz A. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clin Kidney J. 2019;12:629\u201338.","journal-title":"Clin Kidney J"},{"key":"1656_CR37","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.ekir.2021.07.028","volume":"6","author":"R Ramachandran","year":"2021","unstructured":"Ramachandran R, Kumar V, Bharati J, Rovin B, Nada R, Kumar V, et al. Long-term follow-up of cyclical cyclophosphamide and steroids versus tacrolimus and steroids in primary membranous nephropathy. Kidney Int Rep. 2021;6:2653\u201360.","journal-title":"Kidney Int Rep."},{"key":"1656_CR38","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranpus nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66:1199\u2013205.","journal-title":"Kidney Int"},{"key":"1656_CR39","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.3390\/jcm9072178","volume":"9","author":"L Cuarental","year":"2020","unstructured":"Cuarental L, Vali\u00f1o-Rivas L, Mendon\u00e7a L, Saleem M, Mezzano S, Sanz AB, et al. Tacrolimus prevents TWEAK-induced PLA2R expresi\u00f3n in cultured human podocytes. J Clin Med. 2020;9:2178. https:\/\/doi.org\/10.3390\/jcm9072178.","journal-title":"J Clin Med"},{"key":"1656_CR40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"D Altman","year":"1998","unstructured":"Altman D. Confidence intervals for the number needed to treat. Br Med J. 1998;317:1309\u201312.","journal-title":"Br Med J"},{"key":"1656_CR41","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/ndt\/gfy049","volume":"33","author":"P Hamilton","year":"2018","unstructured":"Hamilton P, Kanigicherla D, Venning M, Brenchley P, Meads D. Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a health economic model. Nephrol Dial Transplant. 2018;33:2145\u201355.","journal-title":"Nephrol Dial Transplant"},{"key":"1656_CR42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Eng J Med. 2016;375:454\u201363.","journal-title":"N Eng J Med"},{"key":"1656_CR43","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","volume":"93","author":"A-E Van de Logt","year":"2018","unstructured":"Van de Logt A-E, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, Wetzels J. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93:1016\u20137.","journal-title":"Kidney Int"},{"key":"1656_CR44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","volume":"95","author":"K Dahan","year":"2019","unstructured":"Dahan K, Johannet C, Esteve E, Plaisier E, Debiec H, Ronco P. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody. Kidney Int. 2019;95:233\u20134.","journal-title":"Kidney Int"},{"key":"1656_CR45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","volume":"92","author":"M Rosenzwajg","year":"2017","unstructured":"Rosenzwajg M, Languille E, Debiec H, Hygino H, Dahan K, Simon T, et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int. 2017;92:227\u201337.","journal-title":"Kidney Int"},{"key":"1656_CR46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani D, de Ramon GE, Danieli MG, et al. The 10-year follow-up of the Euro-Lupus nephritis trial comparing two low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1656_CR47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ckj\/sfw152","volume":"10","author":"V Mathrani","year":"2017","unstructured":"Mathrani V, Alejmi A, Griffin S, Roberts G. Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy. Clin Kidney J. 2017;10:450\u20134.","journal-title":"Clin Kidney J"},{"key":"1656_CR48","doi-asserted-by":"crossref","first-page":"943","DOI":"10.34067\/KID.0002802020","volume":"1","author":"L Luzardo","year":"2020","unstructured":"Luzardo L, Ottati G, Cabrera J, Trujillo H, Garau M, Bedat CG, et al. Substitution of oral for intravenous cyclophosphamide in membranous nephropathy. Kidney360. 2020;1:943\u20139.","journal-title":"Kidney360."},{"key":"1656_CR49","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.04.014","author":"R Zonozi","year":"2021","unstructured":"Zonozi R, Laliberte K, Huizenga NR, Rosenthal JK, Jeyabalan A, Collins AB, et al. Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow-up. Am J Kidney Dis. 2021. https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.014.","journal-title":"Am J Kidney Dis"},{"key":"1656_CR50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7326\/0003-4819-116-6-438","volume":"116","author":"RJ Falk","year":"1992","unstructured":"Falk RJ, Hogan SL, Muller KE, Jennette C, Glomerular Disease Collaborative Network. Treatment of progressive membranous glomerulopathy. Ann Int Med. 1992;116:438\u201345.","journal-title":"Ann Int Med."},{"key":"1656_CR51","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Fervenza FC, Zand L. Successful treatment of patient with refractory PLA2R-associated membranous nephropathy with obitunuzumab: a report of 3 cases. Am J Kidney Dis. 2020;76:883\u20138.","journal-title":"Am J Kidney Dis"},{"key":"1656_CR52","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","volume":"5","author":"S Sethi","year":"2020","unstructured":"Sethi S, Kumar S, Lim K, Jordan SC. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep. 2020;5:1515\u20138.","journal-title":"Kidney Int Rep."},{"key":"1656_CR53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Eng J Med. 2020;383:1117\u201328.","journal-title":"N Eng J Med"},{"key":"1656_CR54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfz086","volume":"35","author":"C Barret","year":"2020","unstructured":"Barret C, Willcoks LC, Jones RB, Tarzi RM, Henderson RB, Cai G, et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in membranous nephropathy. Nephrol Dial Transplant. 2020;35:599\u2013606.","journal-title":"Nephrol Dial Transplant"},{"key":"1656_CR55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol. 2016;12:232\u201340.","journal-title":"Nat Rev Nephrol"},{"key":"1656_CR56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","volume":"29","author":"A Segarra","year":"2020","unstructured":"Segarra A, Arredondo AV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-centre experience. Lupus. 2020;29:118\u201325.","journal-title":"Lupus"},{"key":"1656_CR57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","volume":"27","author":"C Hartono","year":"2014","unstructured":"Hartono C, Chung M, Kuo SF, Seshan SV, Muthukumar T. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J Nephrol. 2014;27:103\u20136.","journal-title":"J Nephrol"},{"key":"1656_CR58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000515087","volume":"1","author":"AS Geara","year":"2021","unstructured":"Geara AS, Bhoj V, Hogan JJ. Bortezomib treatment for refractory PLA2R-positive membranous nephropathy. Glom Dis. 2021;1:40\u20133.","journal-title":"Glom Dis."},{"key":"1656_CR59","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2021.04.011","volume":"100","author":"S Salhi","year":"2021","unstructured":"Salhi S, Ribes D, Colombat M, Fortenfant F, Faguer S. Bortezomib plus dexamethasone for rituximab-resistant PLA2R + membranous nephropathy. Kidney Int. 2021;100:708\u20139.","journal-title":"Kidney Int"},{"key":"1656_CR60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW van de Donk","year":"2016","unstructured":"van de Donk NW, Janmaat ML, Mutis T, van Bueren JJL, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270:95\u2013112.","journal-title":"Immunol Rev"},{"key":"1656_CR61","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, et al. Immunnosupression for progressive membranous nephropathy: a UK randomized controlled trial. Lancet. 2013;381:744\u201351.","journal-title":"Lancet"},{"key":"1656_CR62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","volume":"5","author":"N Hanset","year":"2020","unstructured":"Hanset N, Esteve E, Plaisier E, Johanet C, Michel PA, Boffa J-J, et al. Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD. Kidney Int Rep. 2020;5:331\u20138.","journal-title":"Kidney Int Rep."},{"key":"1656_CR63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","volume":"95","author":"J Floege","year":"2019","unstructured":"Floege J, Barbour SJ, Cattran D, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95:268\u201380.","journal-title":"Kidney Int"},{"key":"1656_CR64","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck","year":"2011","unstructured":"Beck LH, Fervenza FC, Beck DM, Bonegio RGB, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22:1543\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR65","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pell\u00e9 T, Gaspari F, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcomes of membranous nephropathy. J Am Soc Nephrol. 2015;26:2545\u201358.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","volume":"32","author":"S Sethi","year":"2021","unstructured":"Sethi S. New antigens in membranous nephropathy. J Am Soc Nephrol. 2021;32:268\u201378.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese AS, Glassock R, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28:421\u201330.","journal-title":"J Am Soc Nephrol"},{"key":"1656_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004293.pub4","volume":"11","author":"TC von Groote","year":"2021","unstructured":"von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021;11: CD004293. https:\/\/doi.org\/10.1002\/14651858.CD004293.pub4.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01656-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01656-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T10:09:38Z","timestamp":1644833378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01656-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1656"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01656-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"21 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research by the authors was supported by FIS\/Fondos FEDER (PI18\/01366, PI19\/00588, PI19\/00815, DTS18\/00032, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18\/00064 and PERSTIGAN AC18\/00071, ISCIII-RETIC REDinREN RD016\/0009), Sociedad Espa\u00f1ola de Nefrolog\u00eda, Fundaci\u00f3n Renal I\u00f1igo \u00c1lvarez de Toledo (FRIAT), and Comunidad de Madrid en Biomedicina B2017\/BMD-3686 CIFRA2-CM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jorge Rojas-Rivera has received consultancy or speaker fees from GlaxoSmithKline, Alexion Pharma Spain S.L., and Otsuka Pharmaceuticals. Alberto Ortiz has received consultancy or speaker fees or travel support from Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Otsuka, and Vifor Fresenius Medical Care Renal Pharma and is a Director of the Catedra Mundipharma-UAM of Diabetic Kidney Disease and the Catedra AstraZeneca-UAM of Chronic Kidney Disease and Electrolytes. F.C. Fervenza reports having consultancy agreements with Alexion Pharmaceuticals, Alnylam, and ByoCrystal; receiving research funding from Chemocentryx, Genentech Inc., Janssen Pharmaceutical, and Questcor\/Mallinckrodt; being a scientific advisor for, or member of, Kidney International, Nephrology, Nephrology Dialysis Transplantation, and UpToDate; and receiving honoraria from UpToDate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All analysis and graphics for this review were realized with MS Excel for Windows and Stata version 15.0 for Windows.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Jorge Rojas-Rivera: conception of the study, literature search, data analysis, elaboration of tables and figures, drafting, critical review, and approval of the final manuscript. Alberto Ortiz: rafting, modifications and corrections, elaboration of tables and figures, critical review, and approval of the final manuscript. Fernando C. Fervenza: drafting, modifications, and corrections, critical review, and final approval of the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}